Početna › Difuzni veliki B-stanični limfom › South Carolina
Kliničke studije za Difuzni veliki B-stanični limfom u državi South Carolina
4 studija za Difuzni veliki B-stanični limfom traži sudionike na lokacijama u državi South Carolina.
Gradovi u državi South Carolina
Službeni tekst studije (engleski)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Prisma Health - Upstate ( Site 0158), Greenville
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Medical University of South Carolina ( Site 0153), Charleston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06890884Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- i još 5
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. velj 2026. · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Medical University of South Carolina, Charleston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. lis 2025. · NCT05890352Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.